Ken O'Day, PhD, MPA

Number Needed to Treat Analysis of the SAGE-217 Phase 2 Clinical Trial Results in Major Depressive Disorder

Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to tre...

Ken O'Day , PhD, MPA;

Vijayveer Bonthapally , PhD;

Alix Arnaud , MSc;

Ellison Suthoff , MBA, BS ;

Katie Stenson , MSc;

Brian Werneburg , PhD;

Paul Hodgkins , PhD, MSc;

Jeffrey Jonas , MD;

Kellie Meyer , PharmD, MPH;

11/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 13 ⁠–⁠ November 16

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

See Full Calendar

Ken O'Day, PhD, MPA

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products